The China Growth Conference is sponsored by leading financial organizations that are active in the Chinese market. Conference sponsors benefit by increasing their visibility and brand recognition with an audience that is focused on China, as well as developing relationships with potential clients and strengthening ties with current ones.

Adam Friedman, AFA's principal, commented, "Our conference has proven to be an ideal forum from the perspective of Chinese companies looking to meet investors, as well as U.S. investors seeking quality Chinese companies in which to invest. Having started our China Division in 2004, our experience enables us to bring professionals together in a dynamic and mutually beneficial venue. We look forward to introducing some of the most exciting Chinese companies to a U.S. investor audience. Our partnership with Nortia Capital Partners has demonstrated that our conference continues to expand in terms of interest, attendance and -- importantly -- impact."

The fee for companies to present at the conference is $6,000. Sponsorships are available at a fee of $10,000. For additional information about presenting at or sponsoring the conference, contact Marilyn Gerber, marilyn@adam-friedman.com, 212.981.2529, ext. 11. There is no cost to attend the conference and attendees can register online. Additional information and registration forms are available at http://www.adam-friedman.com/china/Fall2008/.

SOURCE: Adam Friedman Associates (AFA)

Adam Friedman Associates 
Hadas Streit, 212-981-2529 X 22 
hadas@adam-friedman.com

The Asia Society and the China Institute are also participating in the Conference as Outreach Partners.

Adam Friedman, AFA's principal, commented, "We are very happy to welcome this esteemed group to our growing sponsor roster. We are confident that their presence will add a positive dimension to our Conference."

Sponsorship opportunities are still available. Additionally, there are a few more speaking slots remaining for Chinese companies that are interested in making a presentation to the more than 200 investment bankers, hedge fund managers, buy-and sell-side analysts, venture capitalists, private investors, and other financial professionals who will be in attendance.

Additional information about presenting, sponsoring or attending the Conference is available at http://www.adam-friedman.com/china/Fall2008/. (There is no cost for investors to attend.)

SOURCE: Adam Friedman Associates

Adam Friedman Associates 
Hadas Streit, 212-981-2529, ext. 22 
hadas@adam-friedman.com

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(r) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed on August 11, 2008.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Emisphere Technologies, Inc.

Emisphere Technologies, Inc. 
          Bob Madison, Senior Director Corporate Communications
          973-532-8001 
          bmadison@emisphere.com
 
          Adam Friedman Associates
          Adam Friedman
          212-981-2529, extension 18 
          adam@adam-friedman.com

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(r) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(r) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The website is: www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed on August 11, 2008.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Emisphere Technologies, Inc.

Emisphere Technologies, Inc.
          Bob Madison, Senior Director Corporate Communications
          973-532-8001
          bmadison@emisphere.com

          Adam Friedman Associates
          Adam Friedman
          212-981-2529, extension 18
          adam@adam-friedman.com